Our Science

Adiso is a Clinical Stage Company with an Innovative Pipeline of Multimodal, Locally Acting Small Molecules and Single Strain Live Biotherapeutic Products for Modulating Inflammation

We focus on chronic and progressive inflammatory diseases with a high unmet need for targeted therapies

Dysregulated inflammation is central to many serious diseases and current treatment paradigms are inadequate to stop disease progression. We see a significant opportunity to serve patients and the overall marketplace with our highly differentiated and locally acting therapies across a wide range of inflammatory diseases.

ADISO PORTFOLIO
Multimodal activity contributes to efficacy while local targeting diminishes risk of off-target effects including immunosuppression

Our Pipeline

Small Molecule Modulator of Neutrophil Trafficking and Activation

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FRP1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study, ADS051 was safe and well-tolerated and restricted to the gut with limited systemic exposure.

First-In-Class Small Molecule Inhibitor of the NLRP1 and 3 Inflammasomes

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS032

Respiratory Inflammation

ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide
range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases.

Single Strain Live Biotherapeutic Product (SS-LBP) Platform

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS024 CDI

Prevention of CDI Recurrence

ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 possesses a dual mechanism of action. It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. difficile while maintaining other components of the microbiome. ADS024 is a single strain multimodal LBP and is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.

ADS024 UC

Ulcerative Colitis

ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 modulates inflammation as a single strain multimodal LBP and has been shown to reduce neutrophil trafficking through the colonic epithelium. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.

ADS00X

Neuroinflammation

ADS00X has demonstrated pre-clinical efficacy in the 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis.